A phase IIb trial of Heartcel in patients with moderate to severe adult heart failure

Trial Profile

A phase IIb trial of Heartcel in patients with moderate to severe adult heart failure

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Immunomodulatory-progenitor-cell-therapy-Celixir (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors Celixir
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to a Celixir media release, this trial is expected to complete in 2020.
    • 08 Jan 2018 According to a Celixir media release, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top